Retinitis Pigmentosa Clinical Trials

Find Retinitis Pigmentosa Clinical Trials Near You

A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis PigmentosaAssociated With Usher Syndrome

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision. Participants will: Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Able to comprehend and willing to sign an informed consent form (OCF) and adhere to the study protocol.

• Diagnosed with RP associated with Usher syndrome.

• EZ width ≥ 500 microns, which includes the fovea in each eye at Visit 1.

• All edges of the EZ area in both eyes can be visualized at Visit 1 (Screening).

• Have at least 20 detectable points on the MAIA grid in at least one eye at the Screening and Baseline visits (same eye for both visits).

• On stable dose of medications associated with other conditions for at least one month.

• Willing to use contraception during study (for anyone of childbearing potential).

Locations
United States
Texas
Retina Foundation of the Southwest
RECRUITING
Dallas
Contact Information
Primary
Nacuity Pharmaceuticals
info@nacuity.com
+1-817-336-3000
Time Frame
Start Date: 2026-10
Estimated Completion Date: 2029-04
Participants
Target number of participants: 80
Treatments
Placebo_comparator: Placebo
Oral Placebo Tablet (BID)
Experimental: NPI-001
Oral N-Acetyl Cysteine Amide Tablet (250 mg BID)
Sponsors
Collaborators: Foundation Fighting Blindness
Leads: Nacuity Pharmaceuticals, Inc.

This content was sourced from clinicaltrials.gov